50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
OTCMKTS:BPMUF

Basilea Pharmaceutica - BPMUF Stock Forecast, Price & News

$41.00
0.00 (0.00%)
(As of 09/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$41.00
▼
$41.00
50-Day Range
$41.00
▼
$41.00
52-Week Range
$41.00
▼
$41.00
Volume
N/A
Average Volume
0 shs
Market Capitalization
$485.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$84.00

Basilea Pharmaceutica MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
104.9% Upside
$84.00 Price Target
Short Interest
Bearish
3.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.47) to $0.56 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

See Top Rated MarketRank™ Stocks Here
BPMUF stock logo

About Basilea Pharmaceutica (OTCMKTS:BPMUF) Stock

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

Receive BPMUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter.

BPMUF Stock News Headlines

September 21, 2022 | finance.yahoo.com
Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium
September 20, 2022 | finance.yahoo.com
Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and updates financial guidance
September 8, 2022 | finance.yahoo.com
Basilea announces sale of preclinical oncology program to Nodus Oncology
September 7, 2022 | finance.yahoo.com
Basilea announces CHF 75 million senior secured loan agreement with Athyrium for non-dilutive refinancing of convertible bonds due in December 2022
August 16, 2022 | finance.yahoo.com
Basilea reports strong financial half-year results and progress in the implementation of new anti-infectives strategy
July 12, 2022 | finance.yahoo.com
Basilea announces Zevtera® (ceftobiprole) marketing authorization in Brazil
June 28, 2022 | finance.yahoo.com
Basilea announces positive results of phase 3 ERADICATE study with ceftobiprole in Staphylococcus aureus bacteremia (SAB)
June 27, 2022 | finance.yahoo.com
Basilea reports progress on the implementation of its strategy to focus on anti-infectives
June 24, 2022 | finance.yahoo.com
Basilea announces approval for additional formulation of antifungal Cresemba® (isavuconazole) in China
June 17, 2022 | finance.yahoo.com
Cresemba® sales in Asia Pacific region trigger sales milestone payment to Basilea from Pfizer
May 5, 2022 | finance.yahoo.com
Basilea Pharmaceutica (BSLN): Renewed Focus on Anti-Infectives
April 27, 2022 | finance.yahoo.com
Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase Chemical Diversity Center
March 8, 2022 | finance.yahoo.com
Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress
February 18, 2022 | seekingalpha.com
Basilea Pharmaceutica AG 2021 Q4 - Results - Earnings Call Presentation
February 15, 2022 | finance.yahoo.com
Basilea to become a leading anti-infectives company backed by strong financial results 2021
January 13, 2022 | finance.yahoo.com
Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China
January 11, 2022 | finance.yahoo.com
Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections
January 10, 2022 | finance.yahoo.com
Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-position
January 7, 2022 | finance.yahoo.com
Strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million sales milestone payment to Basilea
January 6, 2022 | finance.yahoo.com
Basilea reports on portfolio progress made in 2021
December 21, 2021 | finance.yahoo.com
Basilea receives USD 10 million milestone payment related to approval of antifungal Cresemba® (isavuconazole) in China
December 19, 2021 | markets.businessinsider.com
Basilea Pharma: FDA Allows To Proceed With Phase 1 Study For BAL0891
December 17, 2021 | finance.yahoo.com
Basilea announces FDA approval of Investigational New Drug application for novel oncology drug candidate BAL0891
December 8, 2021 | finance.yahoo.com
Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 10 million sales milestone payment to Basilea
November 16, 2021 | finance.yahoo.com
Basilea announces submission of Investigational New Drug application for novel oncology drug candidate BAL0891
See More Headlines
Receive BPMUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter.

BPMUF Company Calendar

Today
9/28/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BPMUF
CUSIP
N/A
CIK
N/A
Web
www.basilea.com
Phone
(161) 606-1111
Fax
41-61-606-1112
Employees
154
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$84.00
High Stock Price Forecast
$84.00
Low Stock Price Forecast
$84.00
Forecasted Upside/Downside
+104.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.38
Quick Ratio
1.25

Sales & Book Value

Annual Sales
$162.08 million
Price / Sales
3.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($5.97) per share
Price / Book
-6.87

Miscellaneous

Outstanding Shares
11,850,000
Free Float
N/A
Market Cap
$485.85 million
Optionable
Not Optionable
Beta
0.96

Key Executives

  • Mr. David Veitch (Age 57)
    Chief Exec. Officer
    Comp: $1.15M
  • Mr. Adesh Kaul (Age 48)
    Chief Financial Officer
  • Dr. Gerrit Hauck Ph.D. (Age 58)
    Chief Technology Officer
  • Dr. Laurenz Kellenberger Ph.D. (Age 55)
    Chief Scientific Officer
  • Dr. Marc Engelhardt M.D. (Age 58)
    Chief Medical Officer
  • Dr. Peer Nils Schroder
    Head of Corp. Communications & Investor Relations
  • Mr. Damian Heller (Age 56)
    Gen. Counsel & Corp. Sec.
  • Ms. Ursula Eberhardt (Age 60)
    Head of Global HR
  • Mr. Lutz Wevelsiep
    Head of Regulatory Affairs
  • Mr. Dietrich Stüber
    Head of Internal Services

Key Competitors

View All Competitors













BPMUF Stock - Frequently Asked Questions

Should I buy or sell Basilea Pharmaceutica stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Basilea Pharmaceutica in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BPMUF shares.
View BPMUF analyst ratings or view top-rated stocks.

What is Basilea Pharmaceutica's stock price forecast for 2022?

1 brokers have issued 1-year price targets for Basilea Pharmaceutica's shares. Their BPMUF share price forecasts range from $84.00 to $84.00. On average, they expect the company's stock price to reach $84.00 in the next twelve months. This suggests a possible upside of 104.9% from the stock's current price.
View analysts price targets for BPMUF or view top-rated stocks among Wall Street analysts.

How have BPMUF shares performed in 2022?

Basilea Pharmaceutica's stock was trading at $41.00 at the beginning of 2022. Since then, BPMUF stock has increased by 0.0% and is now trading at $41.00.
View the best growth stocks for 2022 here.

What is Basilea Pharmaceutica's stock symbol?

Basilea Pharmaceutica trades on the OTCMKTS under the ticker symbol "BPMUF."

How do I buy shares of Basilea Pharmaceutica?

Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Basilea Pharmaceutica's stock price today?

One share of BPMUF stock can currently be purchased for approximately $41.00.

How much money does Basilea Pharmaceutica make?

Basilea Pharmaceutica (OTCMKTS:BPMUF) has a market capitalization of $485.85 million and generates $162.08 million in revenue each year.

How many employees does Basilea Pharmaceutica have?

The company employs 154 workers across the globe.

How can I contact Basilea Pharmaceutica?

Basilea Pharmaceutica's mailing address is Grenzacherstrasse 487, Basel V8, 4058. The official website for the company is www.basilea.com. The company can be reached via phone at (161) 606-1111, via email at investor_relations@basilea.com, or via fax at 41-61-606-1112.

This page (OTCMKTS:BPMUF) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.